Ultragenyx Pharmaceutical announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to achieve the primary endpoint of change from baseline in Bayley-4 cognitive raw score or the key secondary endpoint of net response in the Multidomain Responder Index. The safety profile was consistent with earlier phases, but no efficacy differences supported approval. The company will evaluate the program's future and implement significant expense reductions while supporting its commercial business. Ultragenyx Pharmaceutical Inc. operates in the biopharmaceutical industry, developing treatments for rare genetic diseases.

On August 19, 2026, Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia. The approval is based on positive data from the Phase 3 GlucoGene study, which demonstrated a significant reduction in cornstarch requirements for treated participants compared to placebo. As part of the accelerated approval conditions, Ultragenyx must provide two years of safety and efficacy clinical data from open-label commercial treatment involving 50 patients and 20 control patients through its existing Disease Monitoring Program. The company operates in the biotechnology industry, focusing on gene therapies for rare genetic diseases.

Ultragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Esjay Pharma resolving patent litigation regarding the generic version of DOJOLVI (triheptanoin). The Company granted Esjay a non-exclusive, royalty-free license to market its generic version beginning January 1, 2033, potentially extending to July 1, 2033 if pediatric exclusivity is granted. Similar patent litigation against other ANDA filers remains pending in the U.S. District Court for the District of New Jersey. The settlement will be submitted to the Federal Trade Commission and Department of Justice as required by law. Ultragenyx Pharmaceutical Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare genetic diseases.

Ultragenyx Pharmaceutical Inc. reported second quarter 2026 financial results with total revenue of $214 million, up from $167 million in the prior year period. Crysvita generated $156 million and Dojolvi contributed $27 million. The company reaffirmed its full-year 2026 guidance for total revenue between $730 million and $760 million and combined R&D and SG&A expenses to be flat or slightly down versus 2025. Net loss narrowed to $92 million, or $0.90 per share, compared to a net loss of $115 million in the same quarter last year. Cash, cash equivalents, and marketable securities stood at $436 million as of June 30, 2026. The company highlighted upcoming catalysts including PDUFA dates for DTX401 on August 23, 2026, and UX111 on September 19, 2026, alongside pivotal data readouts for GTX-102 in Angelman syndrome. Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.